The severity of radiation injury in humans is largely determined by high sensitivity of the gastrointestinal (GI) tract, yet no drugs are approved for this indication. This proposal is focused on a novel clinical-stage drug candidate, Protectan CBLB502, a toll-like receptor 5 (TLR5) agonist capable of effective mitigation of otherwise lethal radiation-induced GI injury in mice and non-human primates (NHPs). A comprehensive understanding of mechanisms of action is required for drug development under the FDA Animal Efficacy Rule. Accordingly, the main objective of this proposal is to use mouse and NHP models to characterize in detail the mitigating effect of CBLB502 on various elements of the GI system and to identify cellular and molecular mediators of this effect. Specifically, our multi-institutional collaborative team will: (i) create a comprehensive """"""""histological atlas"""""""" illustrating the mitigating effects of CBLB502 on various elements of GI infrastructure damaged by radiation, (ii) define the target organs that contribute to the GI radiomitigation activity of CBLB502 with specific focus on bone marrow and liver, and (iii) identify primary and secondary cellular and molecular responders to CBLB502 with the expectation of defining molecular conductors of the radiomitigating function of the drug as well as novel efficacy biomarkers. Completion of this program should create a solid mechanistic base for translation of animal data into a well-justified projected human efficacious dose and will be critical for FDA approval of CBLB502 as a medical countermeasure to mitigate GI radiation damage.

Public Health Relevance

Protectan CBLB502, is a clinical stage drug candidate effective against multiple components of Acute Radiation Syndrome including GI injury. Completion of the proposed program will facilitate development and FDA approval of CBLB502 by providing critical insights in the mechanisms of its activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
1RC2AI087616-01
Application #
7865476
Study Section
Special Emphasis Panel (ZAI1-BDP-I (S2))
Program Officer
Dicarlo-Cohen, Andrea L
Project Start
2009-09-26
Project End
2011-08-31
Budget Start
2009-09-26
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$2,844,359
Indirect Cost
Name
Cleveland Biolabs, Inc.
Department
Type
DUNS #
136769820
City
Buffalo
State
NY
Country
United States
Zip Code
14203
Krivokrysenko, Vadim I; Toshkov, Ilia A; Gleiberman, Anatoli S et al. (2015) The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates. PLoS One 10:e0135388
Natarajan, Venkatesh; Komarov, Andrei P; Ippolito, Thomas et al. (2014) Peptides genetically selected for NF-?B activation cooperate with oncogene Ras and model carcinogenic role of inflammation. Proc Natl Acad Sci U S A 111:E474-83
Tukhvatulin, Amir I; Gitlin, Ilya I; Shcheblyakov, Dmitry V et al. (2013) Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-?B, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection. Infect Immun 81:3855-64
Burdelya, Lyudmila G; Brackett, Craig M; Kojouharov, Bojidar et al. (2013) Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A 110:E1857-66
Burdelya, Lyudmila G; Gleiberman, Anatoli S; Toshkov, Ilia et al. (2012) Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 83:228-34
Krivokrysenko, Vadim I; Shakhov, Alexander N; Singh, Vijay K et al. (2012) Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther 343:497-508
Yoon, Sung-il; Kurnasov, Oleg; Natarajan, Venkatesh et al. (2012) Structural basis of TLR5-flagellin recognition and signaling. Science 335:859-64
Spengler, Mary L; Kuropatwinski, Karen K; Comas, Maria et al. (2012) Core circadian protein CLOCK is a positive regulator of NF-?B-mediated transcription. Proc Natl Acad Sci U S A 109:E2457-65
Gudkov, Andrei V; Gurova, Katerina V; Komarova, Elena A (2011) Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2:503-16